natgillin/translations-raw huggingface dataset:
Treatment must be under the supervision of a healthcare professional experienced in the management of opioid dependence/addiction. 
Zdravljenje mora potekati pod nadzorom zdravstvenega strokovnjaka, ki ima izkušnje z zdravljenjem odvisnosti od opioidov oz. z zasvojenostjo z opioidi.
• Opioid analgesics: Adequate analgesia may be difficult to achieve when administering a full opioid agonist in patients receiving buprenorphine. 
• opioidnimi analgetiki: pri bolnikih, ki prejemajo buprenorfin in jim damo polne opioidne agoniste, je težko doseči zadostno analgezijo.
hypotension, respiratory depression); 
hipotenzijo, depresijo dihanja in smrt.
While on Sixmo, situations may arise where patients need acute pain management or anaesthesia. 
Med zdravljenjem z zdravilom Sixmo lahko pride do situacij, ko bodo bolniki potrebovali obvladovanje akutne bolečine ali anestezijo.
Reproductive system and breast disorders uncommon dysmenorrhoea, erectile dysfunction 
Motnje reprodukcije in dojk občasni dismenoreja, erektilna disfunkcija
Risk of serious complications of insertion and removal of implants Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants (see section 4.4). 
Redki, toda hudi zapleti, vključno s poškodbo živcev in migracijo, katere posledica sta embolija in smrt, so lahko posledica nepravilne vstavitve zdravila v obliki implantatov (glejte poglavje 4.4).
Figure 2: Cumulative Distribution Function of the Percentage of Urine Samples Negative for Opioids in Weeks 1-24 (co-primary endpoint 1), Study PRO-806 (ITT Population) 
Slika 2: Kumulativna funkcija porazdelitve v odstotkih vzorcev urina, ki so bili negativni na opioide, od 1. do 24. tedna (primarni sočasno opazovani dogodek 1), študija PRO-806 (populacija ITT)
• insertion site and date 
• mesto in datum vstavitve,
If implants for repeat treatment are not inserted on the same day as removal of previous implants, individuals should be maintained on a fixed dose of 2 to 8 mg/day of sublingual buprenorphine, as clinically indicated, until repeat treatment occurs. 
Če implantatov za ponovljeno zdravljenje ne vstavite isti dan, ko ste odstranili prejšnje implantate, je treba posameznikom do uvedbe ponovljenega zdravljenja dajati fiksni odmerek od 2 do 8 mg/dan podjezičnega buprenorfina, kot je klinično indicirano.
• drug withdrawal syndrome, such as sweating, feeling hot and cold 
• sindrom odtegnitve od drog, na primer potenje, občutek vročine ali mraza,
Please attend all of these necessary appointments. 
Držite se vseh potrebnih terminov pri zdravniku.
Instruct the patient to apply an ice pack to the arm for 40 minutes every two hours for first 24 hours, then as needed. 
Bolniku naročite, naj v prvih 24 urah na roki drži ledeni obkladek 40 minut vsaki dve uri, kasneje pa po potrebi.
Sixmo contains the active substance buprenorphine, which is a type of opioid medicine. 
Kaj je zdravilo Sixmo in za kaj ga uporabljamo Zdravilo Sixmo vsebuje učinkovino buprenorfin, ki je vrsta opioidnega zdravila.
Precipitation of opioid withdrawal syndrome 
Povzročitev sindroma odtegnitve od opioidov
Buprenorphine is extensively metabolized in the liver and increased plasma levels were found to be increased in patients with moderate and severe hepatic impairment. 
Buprenorfin se v veliki meri presnavlja v jetrih, pri bolnikih z zmerno do hudo okvaro jeter so bile opažene povišane ravni v plazmi.
• minimal to no desire or need to abuse opioids 
• minimalna želja/potreba po jemanju opioidov ali odsotnost te želje/potrebe,
• medicines which calm, induce sleep or relax muscles, with active substance names ending with “azepam” This combination may result in death due to breathing depression. 
• zdravila za pomiritev, uspavanje ali za sproščanje mišic in vsebujejo učinkovino, katere ime se konča na „azepam“;
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance < 30 mL/min) (see sections 4.2 and 5.2). 
Pri odmerjanju pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) je priporočljiva previdnost (glejte poglavji 4.2 in 5.2).
Risk of expulsion 
Tveganje iztisa
In urine, most of the buprenorphine and norbuprenorphine was conjugated (buprenorphine: 1% free and 9.4% conjugated; norbuprenorphine: 2.7% free and 11% conjugated). 
prostega in 9,4 % konjugiranega; norbuprenorfin: 2,7 % prostega in 11 % konjugiranega).
Instruct the patient that the pressure bandage can be removed after 24 hours and the adhesive bandage in three to five days. 
Bolniku povejte, da lahko kompresijski povoj sname po 24 urah, obliž pa po treh do petih dneh.
Table 5: Implant breakage in Sixmo double-blind Phase 3 studies Current technique and training PRO-806 
Preglednica 5: Zlom implantata v dvojno slepih študijah zdravila Sixmo 3. faze
Figure 1: Cumulative Distribution Function of the Percentage of Urine Samples Negative for Opioids in Weeks 1-16, Study PRO-805 (ITT) 
Slika 1: Kumulativna funkcija porazdelitve v odstotkih vzorcev urina, ki so bili negativni na opioide, od 1. do 16. tedna, študija PRO-805 (ITT)
If Sixmo implants are not immediately replaced upon removal, patients should be maintained on sublingual buprenorphine (2 to 8 mg/day), as clinically indicated, until Sixmo treatment is resumed. 
Če implantatov Sixmo ne zamenjate takoj po odstranitvi, morajo bolniki do nadaljevanja zdravljenja z zdravilom Sixmo prejemati podjezični buprenorfin (2 do 8 mg/dan), kot je klinično indicirano.
Apply an ice pack on the arm for 40 minutes every two hours for the first 24 hours, then as needed. 
V prvih 24 urah na roki držite ledeni obkladek 40 minut vsaki dve uri, kasneje pa po potrebi.
• alcohol pad 
• alkoholna blazinica,
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance < 30 mL/min) (see sections 4.4 and 5.2). 
Pri odmerjanju pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) je priporočljiva previdnost (glejte poglavji 4.4 in 5.2).
• 1 implant applicator 
• 1 aplikator za implantate.
• Avoid moving implants around under the skin or gain a lot of weight after insertion of Sixmo as this may make it difficult to locate implants. 
• Po vstavitvi zdravila Sixmo ne premikajte implantatov pod kožo in ne pridobite preveč na telesni masi, saj bi zaradi tega lahko otežili iskanje implantatov ob odstranjevanju.
Treatment with Sixmo 
Zdravljenje z zdravilom Sixmo
• A number of cases of death due to breathing depression have been reported while on buprenorphine. 
• Med uporabo buprenorfina so poročali o številnih primerih smrti zaradi depresije dihanja.
• clarithromycin, erythromycin, troleandomycin: medicines to treat bacterial infections 
• klaritromicin, eritromicin, troleandomicin: zdravila za zdravljenje bakterijskih okužb; • nefazodon: zdravilo za zdravljenje depresije;
If pregnancy occurs during treatment with Sixmo the benefit to the patient should be weighed against the risk to the foetus. 
Če med zdravljenjem z zdravilo Sixmo ženska zanosi, je treba pretehtati koristi za bolnico in tveganja za plod.
• fever, feeling cold, discomfort 
• zvišana telesna temperatura, občutek mraza, nelagodje,
* Implant site adverse drug reaction (*) Observed as implant and non-implant site adverse drug reaction ** Reported with other approved buprenorphine only medicinal product *** Post-marketing data only 
(*) Opaženo kot neželeni dogodek v povezavi z mestom implantata ali brez povezave z mestom implantata ** Poročano pri uporabi drugih odobrenih zdravil, ki vsebujejo samo buprenorfin
Preparations for handling or administering the medicinal product 
Subkutana uporaba Priprava na ravnanje z zdravilom ali dajanje zdravila
Step 8: While holding the obturator in place on the arm, retract the cannula along the obturator, leaving the implant in place (Figure 11). 
8. korak: Medtem ko mandren držite pri miru na nadlakti, kanilo vlecite nazaj vzdolž mandrena, s čimer bo implantat ostal na mestu (slika 11).
The mean doses per week in Sixmo subjects in PRO-805 and PRO-806 studies were 5.16 mg and 3.16 mg, with relatively low mean days of use per week of 0.45 and 0.31, respectively. 
V študijah PRO-805 in PRO-806 je bil povprečni odmerek na teden pri osebah, zdravljenih z zdravilom Sixmo, 5,16 mg oz. 3,16 mg, z relativno nizkim povprečnim številom
New implants will be inserted in the other arm. 
Najbolje je nove implantate vstaviti še isti dan. Novi implantati se vstavijo v drugo roko.
Step 3: Put on sterile gloves and check the function of the implant applicator by removing the obturator from the cannula and relocking it. Clean the insertion site with an antiseptic solution, such as chlorhexidine. 
3. korak: Nadenite si sterilne rokavice in preverite delovanje aplikatorja za implantate tako, da odstranite mandren iz kanile in ga znova vstavite.
Using the surgical marker, mark the location of the implants and the location of the incision. 
S kirurškim markerjem označite mesto implantatov in mesto reza.
• changes in blood levels increased enzyme levels: aspartate aminotransferase, gamma-glutamyltransferase, blood lactate dehydrogenase, lipase, amylase decreased enzyme levels: alkaline phosphatase increased bicarbonate level increased bilirubin level - a yellow breakdown substance of the blood pigment increased glucose level decreased cholesterol level decreased haematocrit - the percentage of blood cells on the blood volume decreased haemoglobin - the red blood cell pigment, increased mean cell haemoglobin increase in certain white blood cell count: monocyte, neutrophils decreased cell count: platelets, red blood cells, lymphocytes 
• spremembe vrednosti v krvi: zvišanje ravni encimov: aspartat-aminotransferaze, gama-glutamiltransferaze, laktat dehidrogenaze v krvi, lipaze, amilaze, znižanje ravni encimov: alkalne fosfataze, zvišanje ravni bikarbonata, zvišanje ravni bilirubina - rumena snov, ki nastaja pri razgradnji krvnega pigmenta, zvišanje ravni krvnega sladkorja, znižanje ravni holesterola,
Follow steps 6 through 9 for the insertion of the three remaining implants through the same incision. 
Za vstavljanje preostalih treh implantatov skozi isti rez glejte 6. do 9. korak.
Few cases of protrusion or expulsion of implants, mainly attributed to improper insertion technique, were reported in clinical studies with Sixmo (see section 4.4). 
V kliničnih študijah zdravila Sixmo so poročali o nekaj primerih protruzije ali iztisa implantatov, kar so v večini primerov pripisali nepravilni tehniki vstavitve (glejte poglavje 4.4).
Investigations common alanine aminotransferase increased uncommon aspartate aminotransferase increased, weight decreased, blood lactate dehydrogenase increased, gamma-glutamyl-transferase increased, weight increased, blood alkaline phosphatase decreased, amylase increased, blood bicarbonate increased, blood bilirubin increased, blood cholesterol decreased, blood glucose increased, haematocrit decreased, haemoglobin decreased, lipase increased, lymphocyte count decreased, mean cell haemoglobin increased, mean cell volume abnormal, monocyte count increased, neutrophil count increased, platelet count decreased, red blood cell count decreased 
Preiskave pogosti zvišanje alanin-aminotransferaze občasni zvišanje aspartat-aminotransferaze, zmanjšanje telesne mase, zvišanje laktat dehidrogenaze v krvi, zvišanje gama-glutamil-transferaze, povečanje telesne mase, znižanje alkalne fosfataze v krvi, zvišanje amilaze, zvišanje bikarbonata v krvi, zvišanje bilirubina v krvi, znižanje holesterola v krvi, zvišanje glukoze v krvi, znižanje hematokrita, znižanje hemoglobina, zvišanje lipaze, zmanjšano število limfocitov,
Vascular disorders common hot flush, vasodilatation**, hypertension** 
Žilne bolezni pogosti vročinski oblivi, vazodilatacija**, hipertenzija**
What Sixmo contains 
Kaj vsebuje zdravilo Sixmo
Retention in treatment was high in the Sixmo groups, with 65.7% and 64.0% of patients completing studies PRO-805 and PRO-806, respectively. 
65,7 % oziroma 64,0 % bolnikov, ki so bili do konca vključeni v študiji PRO-805 oziroma PRO-806.
After insertion of the implants, the doctor will apply a sterile gauze with a pressure bandage to minimize bruising. 
Ko bodo implantati vstavljeni, bo zdravnik namestil sterilno gazo s kompresijskim povojem, da bo zmanjšal nastajanje modric.
In case toxicity or overdose symptoms develop, the removal of the implants and transition to a medicinal product that allows dose adjustment are required. 
Če se pojavijo simptomi toksičnosti ali prevelikega odmerjanja, je treba odstraniti implantate in preiti na zdravilo, ki omogoča prilagajanje odmerka.
When a hepatic event is suspected, liver function evaluation is required, including consideration whether to discontinue treatment with Sixmo. 
Če sumite na jetrni dogodek, je treba oceniti delovanje jeter in razmisliti o prekinitvi zdravljenja z zdravljenje z zdravilom
Follow steps 15 and 16 for the removal of the remaining implants through the same incision. 
Za odstranjevanje preostalih treh implantatov skozi isti rez glejte 15. in 16. korak.
The following equipment is needed for implant insertion under aseptic conditions: 
Za vstavljanje implantata v aseptičnih pogojih je potrebna naslednja oprema:
In the analysis of the CDF (weeks 1 to 16), a statistically significant difference between treatments (p=0.0361) was seen, which was in favour of Sixmo. 
Pri analizi kumulativne funkcije porazdelitve (primarni sočasno opazovani dogodek 1) je bila opažena statistično pomembna razlika med zdravljenji (p< 0,0001), ki je bila v prid zdravilu Sixmo.
Skin and subcutaneous tissue disorders common hyperhidrosis uncommon cold sweat, dry skin, rash, skin lesion, ecchymosis* 
Bolezni kože in podkožja pogosti hiperhidroza občasni mrzel znoj, suha koža, izpuščaj, kožne lezije,
• signs of intoxication or overdose appear (miosis, lip cyanosis, sedation, bradycardia, 
• če se pojavijo znaki zastrupitve ali prevelikega odmerjanja (mioza, cianoza ustnic, sedacija, bradikardija, hipotenzija, depresija dihanja);
After removal of the implant, the doctor will apply a sterile gauze with a pressure bandage to minimize bruising. 
Ko bodo implantati odstranjeni, bo zdravnik namestil sterilno gazo s kompresijskim povojem, da bo zmanjšal nastajanje modric.
Apply liquid adhesive to the skin margins and allow to dry before closing the incision with the thin adhesive strip around 6 mm wide (butterfly strip). 
Na robove kože nanesite tekoče lepilo in pustite, da se posuši, preden rez zaprete s tankim lepilnim trakom širine pribl.
Apply a pressure bandage with sterile gauze to minimize bruising. 
Namestite kompresijski povoj s sterilno gazo, da čim bolj zmanjšate modrice.
Equipment for subcutaneous insertion of Sixmo 
Oprema za subkutano vstavljanje zdravila Sixmo
All patients receiving Sixmo should be monitored for conditions indicative of diversion, or progression of opioid dependence and addictive behaviours suggesting the need for more intensive and structured treatment for substance use. 
Vse bolnike, ki uporabljajo zdravilo Sixmo, je treba spremljati glede znakov, ki kažejo na preusmerjanje uporabe ali poslabšanje odvisnosti od opioidov ter vedenja, ki kaže na zasvojenost,
• a history of connective tissue disease such as scleroderma • a history of recurrent methicillin-resistant Staphylococcus aureus infections (MRSA) 
• ponavljajoče okužbe z bakterijo Staphylococcus aureus, odporno proti metilicinu (MRSA), v zdravstveni zgodovini.
In this double-blind and double-dummy study, patients maintained on doses of sublingual buprenorphine of 8 mg/day or less were transferred to 4 Sixmo implants (and daily sublingual placebo), or sublingual buprenorphine 8 mg/day or less (and 4 placebo implants). 
razporedili v skupino s 4 implantati Sixmo (in dnevnim podjezičnim placebom) ali v skupino s podjezičnim buprenorfinom 8 mg/dan ali manj (in 4 implantati s placebom).
Implant kit: 4 Sixmo implants with 1 applicator 
Komplet implantatov: 4 implantati Sixmo z 1 aplikatorjem 6.6 Posebni varnostni ukrepi za odstranjevanje
ITT=intent-to-treat, SL BPN = sublingual buprenorphine Buprenorphine was not included in urine toxicology assessments. 
ITT = populacija z namenom zdravljenja (intent-to-treat), SL BPN = podjezični buprenorfin
When the first 6-month treatment period is up, a new set of Sixmo implants may be given after removal of the old implants, preferably on the same day. 
Ko preteče prvo 6-mesečno obdobje zdravljenja, vam lahko vstavijo nov komplet implantatov Sixmo, ko odstranijo stare implantate.
Instructions for subcutaneous insertion of Sixmo 
Navodila za subkutano vstavljanje zdravila Sixmo
• the patient experiences withdrawal symptoms, e.g. sweating, lacrimation, yawning, nausea, 
• če ima bolnik odtegnitvene simptome, npr. potenje, solzenje, zehanje, navzea, bruhanje,
Withdraw the cannula until the hub is flush with the obturator, then twist the obturator clockwise to lock onto the cannula (Figure 12). 
Kanilo pomikajte nazaj, dokler nastavek ni poravnan z mandrenom, nato mandren zasučite v smeri urnega kazalca, da se zaklene na kanilo (slika 12).
• thin adhesive strip around 6 mm wide (butterfly strip) 
6 mm (metuljasti trak).
• have had an increased formation of scare tissue 
• če se je pri vas pojavilo povečano nastajanje brazgotinastega tkiva.
Patients previously treated with sublingual buprenorphine or sublingual buprenorphine + naloxone, must be on stable doses between 2 to 8 mg/day for at least 30 days and deemed clinically stable by the treating healthcare professional. 
+ naloksonom, morajo vsaj 30 dni jemati stabilne odmerke od 2 do 8 mg/dan in jih mora lečeči zdravnik oceniti kot klinično stabilne.
• pregnancy 
• Nosečnost
In case toxicity or overdose symptoms are observed, the removal of the implants and transition to a medicinal product that allows dose adjustment are required. 
Če opazite simptome toksičnosti ali prevelikega odmerjanja, je treba odstraniti implantate in preiti na zdravilo, ki omogoča prilagajanje odmerka.
Tell your doctor immediately if you have any signs of infection (such as redness or inflammation) at the site of insertion or removal. 
Če se na mestu vstavitve ali odstranjevanja pojavijo znaki okužbe (npr. rdečina ali vnetje) o tem takoj obvestite zdravnika.
The healthcare professional should review the patient's treatment history for concomitant use of CYP3A4 inhibitors prior to initiating Sixmo treatment to determine suitability (see section 4.5). 
CYP3A4, preden uvede zdravljenje z zdravilom Sixmo, da določi njegovo ustreznost (glejte poglavje 4.5).
The physician educational programme, provided in conjunction with the Summary of Product Characteristics (SmPC), should include lecture slides and a detailed, face to face, step-by step description and live demonstration of the surgical procedure for SIXMO insertion and removal. 
Vsebovati mora neposredno usposabljanje v obliki predstavitve in podroben opis postopka po korakih ter predstavitev kirurškega postopka za vstavitev in odstranitev implantata Sixmo.
• have severly reduced liver function 
• če imate močno oslabljeno delovanje jeter;
IMPORTANT INFORMATION Each implant contains buprenorphine hydrochloride equivalent to 74.2 mg of buprenorphine. 
POMEMBNE INFORMACIJE En implantat vsebuje buprenorfinijev klorid v količini, ki ustreza 74,2 mg buprenorfina.
• certain medicines to treat depression or Parkinson's disease, called monoamine oxidase inhibitors, such as phenelzine, isocarboxazid, iproniazid and tranylcypromine 
• rifampicin: zdravilo za zdravljenje tuberkuloze ali določenih drugih okužb; • določena zdravila za zdravljenje depresije ali Parkinsonove bolezni, ki se jim reče zaviralci monoaminooksidaze, kot so fenelzin, izokarboksazid, iproniazid in tranilcipromin.
Removal of Sixmo implants 
Odstranjevanje implantatov Sixmo
• pain affecting muscles and skeleton, neck, limbs, joints 
• bolečina v mišicah in kosteh, v vratu, okončinah in sklepih,
• sterile fenestrated drape 
• sterilna fenestrirana prevleka,
• eye discharge, blurred vision, lacrimal disorder 
• izcedek iz očesa, zamegljen vid, motnje solznih žlez,
Step 4: Lift the edge of the incision opening with the toothed forceps. 
4. korak: S kirurško pinceto privzdignite rob odprtine reza.
Verify the location of the implants by palpation. 
S tipanjem znova preverite lokacijo implantatov.
Place the implant in a glass jar with a lid. Store it safely away from others, especially children. 
Varno ga shranite pred drugimi osebami, zlasti otroki.
The MAH shall ensure that in each MS where SIXMO is marketed, all physicians expected to insert / remove SIXMO subcutaneous (SC) implant are provided with an educational programme, aiming at preventing / minimising the important identified risk of implant protrusion / (spontaneous) expulsion, the important potential risks of damage to nerves or blood vessels during insertion / removal procedure, (dislocation and) migration / missing (partial) implant. 
Namen teh gradiv je preprečevanje/zmanjševanje pomembnega opredeljenega tveganja protruzije/(spontane) ekspulzije implanta in pomembnih možnih tveganj poškodbe živcev ali krvnih žil v postopku vstavljanja/odstranjevanja, (dislokacije in) migracije/manjkajočega (delnega) implantata.
Implants should be inserted in the inner side of the opposite upper arm, following the insertion steps below to locate the appropriate insertion site. 
Izkušenj s ponovno vstavitvijo za obdobje, daljše od 12 mesecev, ni. Implante je treba vstaviti na notranji strani nasprotne nadlakti, pri tem pa je treba upoštevati korake vstavljanja, ki so opisani v nadaljevanju, da najdete ustrezno mesto vstavitve.
What you need to know before you use Sixmo 
Kaj morate vedeti, preden boste vzeli zdravilo Sixmo Ne uporabljajte zdravila Sixmo:
Clean the incision site. 
Očistite mesto reza.
Each implant contains buprenorphine hydrochloride equivalent to 74.2 mg of buprenorphine. 
En implantat vsebuje buprenorfinijev klorid v količini, ki ustreza 74,2 mg buprenorfina.
• dry mouth, wind, indigestion, bloody stool 
• suha usta, vetrovi, prebavne motnje, kri v blatu,
Most frequent implant adverse reactions were implant site pain, implant site pruritus, implant site haematoma, implant site haemorrhage, implant site erythema and implant site rash. 
Najpogostejši neželeni učinki, povezani z implantatom, so bili bolečina na mestu implantata, pruritus na mestu implantata, hematom na mestu implantata, krvavitev na mestu implantata, eritem na mestu implantata in izpuščaj na mestu implantata.
• dilated pupils 
• razširjene zenice,
• pain, such as abdominal pain, bone pain, muscle pain, chest pain, headache 
• druge težave z želodcem in črevesjem, bolezni zob, • bolečina, kot je bolečina v trebuhu, bolečina v kosteh, bolečina v mišicah, bolečina v prsnem košu, glavobol,
Rare but serious complications, including nerve damage and migration resulting in embolism and death, may result from improper insertion of drug implants in the upper arm. Additional complications may include local migration, protrusion, expulsion and implant breakage after insertion or during removal. 
Redki, toda hudi zapleti, vključno s poškodbo živcev in migracijo, katere posledica sta embolija in smrt, so lahko posledica nepravilne vstavitve zdravila v obliki implantatov v nadlaket.
• hot flush, bruising, dilation of blood vessels 
• vročinski oblivi, modrice, razširitev krvnih žil,
• sleep disorder, disinterest 
• motnje spanja, ravnodušnost,
Buprenorphine given under the tongue will be stopped 12 to 24 hours before insertion of Sixmo implants. 
Z jemanjem buprenorfina, ki se daje pod jezik, boste prenehali 12 do 24 ur pred vstavitvijo implantatov Sixmo.
• If an implant comes out after insertion, take the following steps: Schedule an appointment with the inserting doctor as soon as possible. 
• Če implantat po vstavitvi izstopi, ukrepajte takole:
• restlessness, excitement, excitability, abnormal thoughts 
• nemirnost, vznemirjenje, razdražljivost, nenormalne misli, • odvisnost od drog,
Treatment with Sixmo implants 
Zdravljenje z implantati Sixmo